Global Fibromyalgia Treatment Market

Fibromyalgia Treatment Comprehensive Study by Type (Symptomatic, Targeted), Application (Hospitals Pharmacies, Clinic Pharmacy, Retail Drug Stores, Online Pharmacies), Medication Type (Antidepressants, Anticonvulsants, Muscle Relaxants, Narcotic Analgesics, Non-narcotic Analgesics), Diagnosis Type (Laboratory Evaluation, Central Sensitization) Players and Region - Global Market Outlook to 2030

Fibromyalgia Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Fibromyalgia Treatment
Fibromyalgia is a condition that causes lasting and debilitating muscle pain and fatigue. In recent years, cases of road traffic injuries have been rising at an alarming rate, which further leads to the rising prevalence of fibromyalgia as road traffic accidents are likely to develop widespread chronic pain. Psychiatric disorders are increasingly prevalent in the case of fibromyalgia, and post-traumatic stress disorders are also seen with the increasing occurrence rate. Screening for post-traumatic stress disorder symptoms is also an essential part of the assessment process in patients suffering from fibromyalgia. Fibromyalgia treatment is performed by professionals to cure fibromyalgia disease. The Fibromyalgia therapeutics medicine market is driving because factors like a strong pipeline of novel medicine are below the late clinical trial part and also the availableness of a possible client base. Market players are accenting analysis and development, so as to introduce new products within the market and increase treatment choices. restrictive approval and launch of novel fibromyalgia treatment medicine are expected to reinforce fibromyalgia therapeutic medicine market growth over the forecast amount. However, factors like limited prescriptions written by care professionals and also the availableness of other drug products are expected to hamper the market growth.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Fibromyalgia Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer (United States), GlaxoSmithKline (United Kingdom), AstraZeneca (United Kingdom), F. Hoffmann-La Roche AG (Switzerland), Astellas Pharma (Japan), Johnson & Johnson Services, Inc. (United States), SANOFI (France), ABBOTT (United States), NOVARTIS (Switzerland), Eli Lilly and Company (United States), Bayer AG (Germany), ALLERGAN (Ireland), Boehringer Ingelheim (Germany), AbbVie (United States) and Cephalon, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sunovion Pharms Inc (United States), Jazz Pharmaceuticals (Ireland) and Vertical Pharmaceuticals (United States).

Segmentation Overview
AMA Research has segmented the market of Global Fibromyalgia Treatment market by Type (Symptomatic and Targeted), Application (Hospitals Pharmacies, Clinic Pharmacy, Retail Drug Stores and Online Pharmacies) and Region.



On the basis of geography, the market of Fibromyalgia Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Medication Type, the sub-segment i.e. Antidepressants will boost the Fibromyalgia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis Type, the sub-segment i.e. Laboratory Evaluation will boost the Fibromyalgia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increase in The Recommendation of The Treatment by The Doctors

Market Growth Drivers:
Increasing Numerous Cases of Fibromyalgia, Growing Awareness Among the Population and Rising Geriatric Population

Challenges:
Lack of Infrastructure in The Middle- And Low-Income Countries and Difficulty in Diagnosis of The Disease

Restraints:
Higher Adoption of The Off-Label and Generic Drugs

Opportunities:
Increasing Financial Support by The Government and Increasing Research and Development by The Private Operators

Market Leaders and their expansionary development strategies
In June 2020, the Teva pharmaceuticals industries ltd announced that the company will present the new data regarding AJOVY injection that will help to treat fibromyalgia.
In December 2020, Tonix pharmaceuticals announced that the company will achieve positive phase 3 results. The treatment will be used to treat fibromyalgia.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Fibromyalgia Treatment, Venture Capitalists and Private Equity Firms and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Symptomatic
  • Targeted
By Application
  • Hospitals Pharmacies
  • Clinic Pharmacy
  • Retail Drug Stores
  • Online Pharmacies
By Medication Type
  • Antidepressants
  • Anticonvulsants
  • Muscle Relaxants
  • Narcotic Analgesics
  • Non-narcotic Analgesics

By Diagnosis Type
  • Laboratory Evaluation
  • Central Sensitization

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Numerous Cases of Fibromyalgia
      • 3.2.2. Growing Awareness Among the Population
      • 3.2.3. Rising Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Lack of Infrastructure in The Middle- And Low-Income Countries
      • 3.3.2. Difficulty in Diagnosis of The Disease
    • 3.4. Market Trends
      • 3.4.1. Increase in The Recommendation of The Treatment by The Doctors
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Fibromyalgia Treatment, by Type, Application, Medication Type, Diagnosis Type and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Fibromyalgia Treatment (Value)
      • 5.2.1. Global Fibromyalgia Treatment by: Type (Value)
        • 5.2.1.1. Symptomatic
        • 5.2.1.2. Targeted
      • 5.2.2. Global Fibromyalgia Treatment by: Application (Value)
        • 5.2.2.1. Hospitals Pharmacies
        • 5.2.2.2. Clinic Pharmacy
        • 5.2.2.3. Retail Drug Stores
        • 5.2.2.4. Online Pharmacies
      • 5.2.3. Global Fibromyalgia Treatment by: Medication Type (Value)
        • 5.2.3.1. Antidepressants
        • 5.2.3.2. Anticonvulsants
        • 5.2.3.3. Muscle Relaxants
        • 5.2.3.4. Narcotic Analgesics
        • 5.2.3.5. Non-narcotic Analgesics
      • 5.2.4. Global Fibromyalgia Treatment by: Diagnosis Type (Value)
        • 5.2.4.1. Laboratory Evaluation
        • 5.2.4.2. Central Sensitization
      • 5.2.5. Global Fibromyalgia Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Fibromyalgia Treatment (Price)
      • 5.3.1. Global Fibromyalgia Treatment by: Type (Price)
  • 6. Fibromyalgia Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Astellas Pharma (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson Services, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. SANOFI (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. ABBOTT (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. NOVARTIS (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly and Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Bayer AG (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. ALLERGAN (Ireland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Boehringer Ingelheim (Germany)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. AbbVie (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Cephalon, Inc. (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Fibromyalgia Treatment Sale, by Type, Application, Medication Type, Diagnosis Type and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Fibromyalgia Treatment (Value)
      • 7.2.1. Global Fibromyalgia Treatment by: Type (Value)
        • 7.2.1.1. Symptomatic
        • 7.2.1.2. Targeted
      • 7.2.2. Global Fibromyalgia Treatment by: Application (Value)
        • 7.2.2.1. Hospitals Pharmacies
        • 7.2.2.2. Clinic Pharmacy
        • 7.2.2.3. Retail Drug Stores
        • 7.2.2.4. Online Pharmacies
      • 7.2.3. Global Fibromyalgia Treatment by: Medication Type (Value)
        • 7.2.3.1. Antidepressants
        • 7.2.3.2. Anticonvulsants
        • 7.2.3.3. Muscle Relaxants
        • 7.2.3.4. Narcotic Analgesics
        • 7.2.3.5. Non-narcotic Analgesics
      • 7.2.4. Global Fibromyalgia Treatment by: Diagnosis Type (Value)
        • 7.2.4.1. Laboratory Evaluation
        • 7.2.4.2. Central Sensitization
      • 7.2.5. Global Fibromyalgia Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Fibromyalgia Treatment (Price)
      • 7.3.1. Global Fibromyalgia Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Fibromyalgia Treatment: by Type(USD Million)
  • Table 2. Fibromyalgia Treatment Symptomatic , by Region USD Million (2018-2023)
  • Table 3. Fibromyalgia Treatment Targeted , by Region USD Million (2018-2023)
  • Table 4. Fibromyalgia Treatment: by Application(USD Million)
  • Table 5. Fibromyalgia Treatment Hospitals Pharmacies , by Region USD Million (2018-2023)
  • Table 6. Fibromyalgia Treatment Clinic Pharmacy , by Region USD Million (2018-2023)
  • Table 7. Fibromyalgia Treatment Retail Drug Stores , by Region USD Million (2018-2023)
  • Table 8. Fibromyalgia Treatment Online Pharmacies , by Region USD Million (2018-2023)
  • Table 9. Fibromyalgia Treatment: by Medication Type(USD Million)
  • Table 10. Fibromyalgia Treatment Antidepressants , by Region USD Million (2018-2023)
  • Table 11. Fibromyalgia Treatment Anticonvulsants , by Region USD Million (2018-2023)
  • Table 12. Fibromyalgia Treatment Muscle Relaxants , by Region USD Million (2018-2023)
  • Table 13. Fibromyalgia Treatment Narcotic Analgesics , by Region USD Million (2018-2023)
  • Table 14. Fibromyalgia Treatment Non-narcotic Analgesics , by Region USD Million (2018-2023)
  • Table 15. Fibromyalgia Treatment: by Diagnosis Type(USD Million)
  • Table 16. Fibromyalgia Treatment Laboratory Evaluation , by Region USD Million (2018-2023)
  • Table 17. Fibromyalgia Treatment Central Sensitization , by Region USD Million (2018-2023)
  • Table 18. South America Fibromyalgia Treatment, by Country USD Million (2018-2023)
  • Table 19. South America Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 20. South America Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 21. South America Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 22. South America Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 23. Brazil Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 24. Brazil Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 25. Brazil Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 26. Brazil Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 27. Argentina Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 28. Argentina Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 29. Argentina Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 30. Argentina Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 31. Rest of South America Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 33. Rest of South America Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 34. Rest of South America Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 35. Asia Pacific Fibromyalgia Treatment, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 37. Asia Pacific Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 38. Asia Pacific Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 39. Asia Pacific Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 40. China Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 41. China Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 42. China Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 43. China Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 44. Japan Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 45. Japan Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 46. Japan Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 47. Japan Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 48. India Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 49. India Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 50. India Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 51. India Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 52. South Korea Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 53. South Korea Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 54. South Korea Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 55. South Korea Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 56. Taiwan Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 57. Taiwan Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 58. Taiwan Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 59. Taiwan Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 60. Australia Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 61. Australia Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 62. Australia Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 63. Australia Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 68. Europe Fibromyalgia Treatment, by Country USD Million (2018-2023)
  • Table 69. Europe Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 70. Europe Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 71. Europe Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 72. Europe Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 73. Germany Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 74. Germany Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 75. Germany Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 76. Germany Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 77. France Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 78. France Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 79. France Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 80. France Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 81. Italy Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 82. Italy Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 83. Italy Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 84. Italy Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 85. United Kingdom Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 86. United Kingdom Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 87. United Kingdom Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 88. United Kingdom Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 89. Netherlands Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 90. Netherlands Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 91. Netherlands Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 92. Netherlands Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 93. Rest of Europe Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 94. Rest of Europe Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 95. Rest of Europe Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 96. Rest of Europe Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 97. MEA Fibromyalgia Treatment, by Country USD Million (2018-2023)
  • Table 98. MEA Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 99. MEA Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 100. MEA Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 101. MEA Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 102. Middle East Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 103. Middle East Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 104. Middle East Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 105. Middle East Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 106. Africa Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 107. Africa Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 108. Africa Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 109. Africa Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 110. North America Fibromyalgia Treatment, by Country USD Million (2018-2023)
  • Table 111. North America Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 112. North America Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 113. North America Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 114. North America Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 115. United States Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 116. United States Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 117. United States Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 118. United States Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 119. Canada Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 120. Canada Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 121. Canada Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 122. Canada Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 123. Mexico Fibromyalgia Treatment, by Type USD Million (2018-2023)
  • Table 124. Mexico Fibromyalgia Treatment, by Application USD Million (2018-2023)
  • Table 125. Mexico Fibromyalgia Treatment, by Medication Type USD Million (2018-2023)
  • Table 126. Mexico Fibromyalgia Treatment, by Diagnosis Type USD Million (2018-2023)
  • Table 127. Fibromyalgia Treatment: by Type(USD/Units)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Fibromyalgia Treatment: by Type(USD Million)
  • Table 144. Fibromyalgia Treatment Symptomatic , by Region USD Million (2025-2030)
  • Table 145. Fibromyalgia Treatment Targeted , by Region USD Million (2025-2030)
  • Table 146. Fibromyalgia Treatment: by Application(USD Million)
  • Table 147. Fibromyalgia Treatment Hospitals Pharmacies , by Region USD Million (2025-2030)
  • Table 148. Fibromyalgia Treatment Clinic Pharmacy , by Region USD Million (2025-2030)
  • Table 149. Fibromyalgia Treatment Retail Drug Stores , by Region USD Million (2025-2030)
  • Table 150. Fibromyalgia Treatment Online Pharmacies , by Region USD Million (2025-2030)
  • Table 151. Fibromyalgia Treatment: by Medication Type(USD Million)
  • Table 152. Fibromyalgia Treatment Antidepressants , by Region USD Million (2025-2030)
  • Table 153. Fibromyalgia Treatment Anticonvulsants , by Region USD Million (2025-2030)
  • Table 154. Fibromyalgia Treatment Muscle Relaxants , by Region USD Million (2025-2030)
  • Table 155. Fibromyalgia Treatment Narcotic Analgesics , by Region USD Million (2025-2030)
  • Table 156. Fibromyalgia Treatment Non-narcotic Analgesics , by Region USD Million (2025-2030)
  • Table 157. Fibromyalgia Treatment: by Diagnosis Type(USD Million)
  • Table 158. Fibromyalgia Treatment Laboratory Evaluation , by Region USD Million (2025-2030)
  • Table 159. Fibromyalgia Treatment Central Sensitization , by Region USD Million (2025-2030)
  • Table 160. South America Fibromyalgia Treatment, by Country USD Million (2025-2030)
  • Table 161. South America Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 162. South America Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 163. South America Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 164. South America Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 165. Brazil Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 166. Brazil Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 167. Brazil Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 168. Brazil Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 169. Argentina Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 170. Argentina Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 171. Argentina Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 172. Argentina Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 173. Rest of South America Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 174. Rest of South America Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 175. Rest of South America Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 176. Rest of South America Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 177. Asia Pacific Fibromyalgia Treatment, by Country USD Million (2025-2030)
  • Table 178. Asia Pacific Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 179. Asia Pacific Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 180. Asia Pacific Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 181. Asia Pacific Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 182. China Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 183. China Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 184. China Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 185. China Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 186. Japan Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 187. Japan Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 188. Japan Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 189. Japan Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 190. India Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 191. India Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 192. India Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 193. India Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 194. South Korea Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 195. South Korea Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 196. South Korea Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 197. South Korea Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 198. Taiwan Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 199. Taiwan Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 200. Taiwan Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 201. Taiwan Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 202. Australia Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 203. Australia Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 204. Australia Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 205. Australia Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 206. Rest of Asia-Pacific Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 207. Rest of Asia-Pacific Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 208. Rest of Asia-Pacific Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 209. Rest of Asia-Pacific Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 210. Europe Fibromyalgia Treatment, by Country USD Million (2025-2030)
  • Table 211. Europe Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 212. Europe Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 213. Europe Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 214. Europe Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 215. Germany Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 216. Germany Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 217. Germany Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 218. Germany Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 219. France Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 220. France Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 221. France Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 222. France Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 223. Italy Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 224. Italy Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 225. Italy Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 226. Italy Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 227. United Kingdom Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 228. United Kingdom Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 229. United Kingdom Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 230. United Kingdom Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 231. Netherlands Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 232. Netherlands Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 233. Netherlands Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 234. Netherlands Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 235. Rest of Europe Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 236. Rest of Europe Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 237. Rest of Europe Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 238. Rest of Europe Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 239. MEA Fibromyalgia Treatment, by Country USD Million (2025-2030)
  • Table 240. MEA Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 241. MEA Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 242. MEA Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 243. MEA Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 244. Middle East Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 245. Middle East Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 246. Middle East Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 247. Middle East Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 248. Africa Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 249. Africa Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 250. Africa Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 251. Africa Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 252. North America Fibromyalgia Treatment, by Country USD Million (2025-2030)
  • Table 253. North America Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 254. North America Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 255. North America Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 256. North America Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 257. United States Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 258. United States Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 259. United States Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 260. United States Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 261. Canada Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 262. Canada Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 263. Canada Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 264. Canada Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 265. Mexico Fibromyalgia Treatment, by Type USD Million (2025-2030)
  • Table 266. Mexico Fibromyalgia Treatment, by Application USD Million (2025-2030)
  • Table 267. Mexico Fibromyalgia Treatment, by Medication Type USD Million (2025-2030)
  • Table 268. Mexico Fibromyalgia Treatment, by Diagnosis Type USD Million (2025-2030)
  • Table 269. Fibromyalgia Treatment: by Type(USD/Units)
  • Table 270. Research Programs/Design for This Report
  • Table 271. Key Data Information from Secondary Sources
  • Table 272. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Fibromyalgia Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Fibromyalgia Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Fibromyalgia Treatment: by Medication Type USD Million (2018-2023)
  • Figure 7. Global Fibromyalgia Treatment: by Diagnosis Type USD Million (2018-2023)
  • Figure 8. South America Fibromyalgia Treatment Share (%), by Country
  • Figure 9. Asia Pacific Fibromyalgia Treatment Share (%), by Country
  • Figure 10. Europe Fibromyalgia Treatment Share (%), by Country
  • Figure 11. MEA Fibromyalgia Treatment Share (%), by Country
  • Figure 12. North America Fibromyalgia Treatment Share (%), by Country
  • Figure 13. Global Fibromyalgia Treatment: by Type USD/Units (2018-2023)
  • Figure 14. Global Fibromyalgia Treatment share by Players 2023 (%)
  • Figure 15. Global Fibromyalgia Treatment share by Players (Top 3) 2023(%)
  • Figure 16. Global Fibromyalgia Treatment share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer (United States) Revenue: by Geography 2023
  • Figure 20. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 22. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 24. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2023
  • Figure 26. Astellas Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 27. Astellas Pharma (Japan) Revenue: by Geography 2023
  • Figure 28. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2023
  • Figure 30. SANOFI (France) Revenue, Net Income and Gross profit
  • Figure 31. SANOFI (France) Revenue: by Geography 2023
  • Figure 32. ABBOTT (United States) Revenue, Net Income and Gross profit
  • Figure 33. ABBOTT (United States) Revenue: by Geography 2023
  • Figure 34. NOVARTIS (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. NOVARTIS (Switzerland) Revenue: by Geography 2023
  • Figure 36. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 37. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 38. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 39. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 40. ALLERGAN (Ireland) Revenue, Net Income and Gross profit
  • Figure 41. ALLERGAN (Ireland) Revenue: by Geography 2023
  • Figure 42. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 43. Boehringer Ingelheim (Germany) Revenue: by Geography 2023
  • Figure 44. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 45. AbbVie (United States) Revenue: by Geography 2023
  • Figure 46. Cephalon, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 47. Cephalon, Inc. (United States) Revenue: by Geography 2023
  • Figure 48. Global Fibromyalgia Treatment: by Type USD Million (2025-2030)
  • Figure 49. Global Fibromyalgia Treatment: by Application USD Million (2025-2030)
  • Figure 50. Global Fibromyalgia Treatment: by Medication Type USD Million (2025-2030)
  • Figure 51. Global Fibromyalgia Treatment: by Diagnosis Type USD Million (2025-2030)
  • Figure 52. South America Fibromyalgia Treatment Share (%), by Country
  • Figure 53. Asia Pacific Fibromyalgia Treatment Share (%), by Country
  • Figure 54. Europe Fibromyalgia Treatment Share (%), by Country
  • Figure 55. MEA Fibromyalgia Treatment Share (%), by Country
  • Figure 56. North America Fibromyalgia Treatment Share (%), by Country
  • Figure 57. Global Fibromyalgia Treatment: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • GlaxoSmithKline (United Kingdom)
  • AstraZeneca (United Kingdom)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Astellas Pharma (Japan)
  • Johnson & Johnson Services, Inc. (United States)
  • SANOFI (France)
  • ABBOTT (United States)
  • NOVARTIS (Switzerland)
  • Eli Lilly and Company (United States)
  • Bayer AG (Germany)
  • ALLERGAN (Ireland)
  • Boehringer Ingelheim (Germany)
  • AbbVie (United States)
  • Cephalon, Inc. (United States)
Additional players considered in the study are as follows:
Sunovion Pharms Inc (United States) , Jazz Pharmaceuticals (Ireland) , Vertical Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 248 Pages 52 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Fibromyalgia Treatment Market Quantitative research analysis
Global Fibromyalgia Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer (United States), GlaxoSmithKline (United Kingdom), AstraZeneca (United Kingdom), F. Hoffmann-La Roche AG (Switzerland), Astellas Pharma (Japan), Johnson & Johnson Services, Inc. (United States), SANOFI (France), ABBOTT (United States), NOVARTIS (Switzerland), Eli Lilly and Company (United States), Bayer AG (Germany), ALLERGAN (Ireland), Boehringer Ingelheim (Germany), AbbVie (United States) and Cephalon, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increase in The Recommendation of The Treatment by The Doctors" is seen as one of major influencing trends for Fibromyalgia Treatment Market during projected period 2023-2030.
The Fibromyalgia Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Fibromyalgia Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Moyamoya disease Comprehensive Study by Type (Ischemic, Hemorrhagic, Epileptic, Other), Treatment (Non-Surgical {Anti-seizure medications, and Calcium channel blockers}, Surgical {Vascular bypass sur...
$ 3750
Bacteriophages Therapy Comprehensive Study by Type (Lytic, Lysogenic), Application (Diagnostic, Antimicrobial Drug Discovery, Veterinary Medicines, Others), Treatment (Oral, External Application, Sur...
$ 3650
Systemic Mycoses Comprehensive Study by Type (Paracoccidioides, Blastomyces, Histoplasma, Coccidiode), Fungi (Dermatophytes, Yeasts, Molds), Drugs (Amphotericin B, Amphotericin B Itraconazole, Amphot...
$ 3750
Neurotrophic Keratitis Treatment Comprehensive Study by Type (Drugs, Devices, Surgery), Application (Hospitals, Ambulatory Surgical Centers, Others), Route of Administration (Oral, Topical), Distribu...
$ 3450
Metastatic Bone Disease Treatment Comprehensive Study by Type (Medication, Radiation Therapy, Surgical Intervention, Tumor Ablation Therapy), Application (Hospitals, Specialty Clinics, Ambulatory Sur...
$ 3750
Digital Brain Therapy Comprehensive Study by Type (Transcranial random noise stimulation (tRNS), Transcranial direct current stimulation (tDCS), Transcranial alternating current stimulation (tACS), T...
$ 3750